Singapore markets open in 2 minutes

LLY Dec 2022 400.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.84000.0000 (0.00%)
As of 01:54PM EDT. Market open.
Full screen
Previous close2.8400
Open3.0500
Bid1.6300
Ask4.1500
Strike400.00
Expiry date2022-12-16
Day's range2.8400 - 3.0500
Contract rangeN/A
Volume6
Open interest109
  • Zacks

    LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

    The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

  • Motley Fool

    Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today

    Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.

  • Zacks

    Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

    Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.